PET scan to study an HIV-fighting antibody in the body
Part of Infections clinical trials.
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You are either living with HIV or HIV-uninfected (both groups may be allowed)
- If you are living with HIV: you need recent viral load testing within the last 12 months
- If your viral load is suppressed (only in Phase 2): it must be below standard lab detection (example: <40 copies/mL)
- If you are living with HIV: your blood sample must suggest your virus could bind to VRC01
- You must be able to safely complete scans and blood tests (including blood count and kidney/liver limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study measures how raltegravir (an HIV medicine) spreads in the body using a special scan called PET/MR. It may help doctors better understand how to deliver and monitor HIV treatment, even though it focuses on measuring drug behavior rather than curing HIV.
This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
This study uses PET and MRI scans, plus blood tests and memory/thinking questionnaires, to understand what drives brain problems in people living with HIV even during treatment. It may help researchers learn why symptoms happen and how treatment relates to brain function.
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
This study looks at people with HIV who either have not started HIV medicines yet or who recently started/changed them and may develop immune rebound (IRIS). It uses blood tests and optional PET/CT scans and lymph node biopsies to understand what’s happening in the body and to guide care.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.